Expression of Lewis y antigen and integrin αv, β3 in ovarian cancer and their relationship with chemotherapeutic drug resistance

Abstract

ObjectiveThis study investigates the expression of Lewis y antigen, integrin αv, β3 in epithelial ovarian cancer tissues. We further evaluate the relationship between their expression and chemotherapy resistance of ovarian cancer and its possible clinical significance.MethodsTissues of 92 patients with ovarian cancer meeting the inclusion criteria with complete follow-up data were enrolled and divided into chemotherapy resistant group and sensitive group. The expression and relationship of Lewis y antigen and integrin αv, β3 are assessed in paraffin sections using immunohistochemistry and double-labeling immunofluorescence method. Multivariate logistic regression analysis was used to investigate the relationship between age, clinical stage, differentiation, histologic subtype, Lewis y antigen and integrin αv, β3 expression in ovarian cancer patients.ResultsThe expression rates of Lewis y antigen and integrin αv in the resistant group, significantly higher than the rates found in the sensitive group (p <0.05). Multivariate analysis showed that the expression of Lewis y antigen, integrin αv and ovarian cancer’s clinical stage were independent, drug resistance-related risk factors. The expression levels of Lewis y antigen and integrin αv, β3 were positively correlated with each other.ConclusionsA close correlation between Lewis y antigen, integrin αv, β3 and ovarian cancer was observed. Lewis y antigen can influence the biological behavior of a tumor cell as an important composition of integrin αv, β3 by some signal pathway. And the expression of Lewis y antigen, integrin αv and ovarian cancer’s clinical stage are both independent, drug resistance-related risk factors.

A platform for the structural characterization of glycans enzymatically released from glycosphingolipids extracted from tissue and cells

“…A majority of the initial work carried out to determine TACAs in ovarian cancer has been performed using immunohistochemistry. For instance, in several studies involving ovarian cancer tissues and cell lines, the di‐fucosylated Lewis y antigen bearing terminal α1‐2 fucosylation (Fucα1‐2Galβ1‐4GlcNAcβ1‐3(Fucα1‐3)Galβ1‐4Glc) has been identified on surface glycoproteins and glycolipids using specific monoclonal antibodies, and a majority of this antigen was primarily carried by the two major glycoproteins, CA125 and MUC1, in ovarian cancer . While we were not able to detect this structure in the tissue samples analyzed in this study, the presence of the mono‐fucosylated structure, Fucα1‐2Galβ1‐4GlcNAcβ1‐3Galβ1‐4Glc, also known as the H type 2 antigen, was detected in abundance in both the investigated tissue samples.…”

The exosomal integrin α5β1/AEP complex derived from epithelial ovarian cancer cells promotes peritoneal metastasis through regulating mesothelial cell proliferation and migration

“…Integrin functions may thus vary with its different subunits, and it is therefore important to consider integrin subtypes when exploring their effects in different cancers [16][17][18]. In this study, we isolated HPMCs from EOC patients and assessed integrin subtypes.…”

“…Integrins can transduce signals to regulate cell growth, proliferation, differentiation and adhesion, and they are expressed on various cell types including fibroblasts, endothelial cells and immune cells [16]. Some integrins are specifically expressed on EOC cells, such as α5β1, α2β1 and αvβ3 [16][17][18]. Several of them have been found to act as important mediators of EOC metastasis to the mesothelium of the peritoneal cavity.…”

Integrins

“…In ovarian cancer, the expression rate of integrin αv in the resistant group (paclitaxel + carboplatin) is significantly higher than that in the sensitive group. Integrin αv is an independent, drug resistance-related risk factor [167].…”